Xencor, Inc. is a clinical stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases, asthma &amp; allergic diseases and cancer. Its clinical sate XmAb technology is used for the treatment of IgG4-related disease; systemic lupus erythematosus; asthma &amp; allergic diseases; acute myeloid leukemia; B-cell malignancies; and neuroendocrine tumors. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
